Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer.

Trial Details

NCT ID
NCT04865887
Phase
PHASE2
Sponsor
Georgetown University
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • Pembrolizumab
  • Lenvatinib
Locations (sample)
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Augusta, Georgia, United States|33.47097,-81.97484
  • Hackensack, New Jersey, United States|40.88593,-74.04347

Key Eligibility Criteria

  • Female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of locally adva…
  • Patients with progression or intolerance to at least one line of therapy in the locally advanced or metastatic setting will be eligible for this st…
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
  • Not a woman of childbearing potential (WOCBP) as defined OR

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →